Indoco Remedies

Indoco Remedies Financial Leverage

The Financial Leverage (Equity Multiplier) of Indoco Remedies (INDOCO.NS) as of Oct 20, 2026 is 2.76. In the previous year, Financial Leverage (Equity Multiplier) was 2.38 — a change of 16.12% (higher).

Financial Leverage

2.76

YoY

16.12%

Last updated:

Financial Leverage (Equity Multiplier) of Indoco Remedies is 2026 2.76 . Financial Leverage (Equity Multiplier) of Indoco Remedies was 2025 2.38 . It decreases by 16.12% higher compared to the previous year.

The Indoco Remedies Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.90 INR
Jan 1, 2020
1.87 INR
Jan 1, 2021
1.71 INR
Jan 1, 2022
1.64 INR
Jan 1, 2023
1.61 INR
Jan 1, 2024
1.93 INR
Jan 1, 2025
2.38 INR
Jan 1, 2026
2.76 INR
The Indoco Remedies Financial Leverage history
YEARFinancial LeverageYoY
2.76+16.12%
2.38+23.04%
1.93+19.83%
1.61-1.83%
1.64-3.94%
1.71-8.61%
1.87-1.74%
1.90+3.97%
1.83-0.30%
1.84+11.38%
1.65+1.20%
1.63+2.15%
1.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd. manufactures and markets formulations and active pharmaceutical ingredients, offering medicines across therapeutic categories like diabetology, respiratory, and women's health. Its product portfolio includes brands such as Cyclopam, Sensodent-K, Karvol Plus, and Rexidin M, targeting both domestic and international markets. The company serves healthcare providers and consumers through its extensive range of pharmaceutical products, with subsidiaries supporting its global operations. The firm's revenue streams derive from the sale of finished dosage forms and APIs, with key brands like Cital UTI and Kidodent catering to specific medical needs. International markets represent a significant segment, complementing domestic sales, while subsidiaries such as Indoco Remedies Czech sro and Indoco Remedies UK Limited facilitate regional distribution and market expansion. Products like Lignox A and Homide are positioned for niche therapeutic applications, driving demand among healthcare professionals and patients. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Financial Leverage (Equity Multiplier) of Indoco Remedies is 2.76 in 2026.

Financial Leverage (Equity Multiplier) of Indoco Remedies changed from 2.38 to 2.76, representing a 16.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Indoco Remedies

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Indoco Remedies